北京大成（广州）律师事务所 广州市天河区珠江新城珠江东路 6 号 广州周大福金融中心 14-15 层 邮编：510623 14-15F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China dacheng.com dentons.cn 北京大成（广州）律师事务所 关于广州市香雪制药股份有限公司 2023 年第二次临时股东大会法律意见书 编号：02-042023000032-2 号 致：广州市香雪制药股份有限公司 北京大成（广州）律师事务所(以下简称"本所")接受广州市香雪制药股份有 限公司(以下简称"公司")的委托，指派吕晖律师和徐玮盼律师出席公司 2023 年 第二次临时股东大会（以下简称"临时股东大会"），就临时股东大会的召集、召 开程序、出席会议人员资格、表决程序等相关事项出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的下列各项文件： 1．《公司章程》； 2．第九届董事会第十三次会议决议； 3．第九届监事会第九次会议决议； 4．公司独立董事出具的《广州市香雪制药股份有限公司独 ...

广州市香雪制药股份有限公司（以下简称"公司"）于 2023 年 4 月 22 日在 巨潮资讯网披露 2022 年年度报告及其摘要。为了让广大投资者更加深入全面地 了解公司 2022 年度的经营情况，公司将于 2023 年 5 月 5 日（星期五）下午 15 ：00-17：00 在深圳证券交易所提供的"互动易"平台以网络远程的方式举办 2022 年度业绩说明会，投资者可登录"互动易"网站（http://irm.cninfo.com.cn ）进入"云访谈"栏目参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理王永辉先生、独立 董事吴杰先生、董事会秘书徐力先生、财务总监牛晓燕女士。 为充分尊重投资者、提升交流的针对性，现就公司本次年度业绩说明会提前 向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可提前登录"互 动易"网站进入公司本次年度业绩说明会页面进行提问，公司将在年度业绩说明 会上对投资者关注的问题进行回答。欢迎广大投资者积极参与！ 特此公告。 证券代码:300147 证券简称: 香雪制药 公告编号:2023-019 广州市香雪制药股份有限公司 关于举行 2022 年度业绩网 ...

Financial Performance - In the first half of 2015, the company achieved total operating revenue of 752.18 million yuan, a year-on-year increase of 0.77% [3] - The net profit attributable to shareholders was 93.07 million yuan, reflecting a year-on-year growth of 3.76% [3] Marketing Strategy - The company is closely monitoring changes in pharmaceutical industry policies and market strategies, adapting its marketing approach accordingly [3] - Efforts include strengthening channel management, enhancing the marketing team for grassroots medical institutions, and expanding networks to third parties [3] - A nationwide integrated pricing system is being established to manage prices of leading products [3] Research and Development - Increased investment in R&D to accelerate the development and approval of new products [3] - Progress on major R&D projects is reported to be smooth [3] Management and Quality Control - The company has strengthened production site management and safety education in accordance with the new GMP standards [4] - Continuous improvement of the product quality system has led to the company receiving the "Second Quality Award" from the Guangzhou Development Zone [4] Investor Relations - The slowdown in performance growth is attributed to an overall industry deceleration and the impact of refinancing on expansion speed [4] - The company is currently in the process of establishing Huacheng Bank, which is still under regulatory approval [4] - The first phase of the employee stock ownership plan was completed on June 18, 2015, with the company emphasizing its commitment to operational excellence to enhance shareholder value [5] - Plans to expand into the prescription drug market are underway, with a focus on collaboration with hospitals [5]

证券代码：300147 证券简称：香雪制药 编号：20160608 广州市香雪制药股份有限公司投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|----------------------------------| | | | | | 投资者关系活动 | | √特定对象调研 □分析师会议 | | 类别 | □媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | □现场参观 | □ 一对一沟通 | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | | 汇添富基金管理股份有限公司：张韡 | | | 富国基金管理有限公司：娄圣睿 | | | | 华夏基金管理有限公司：陈斌 | | | | | 易方达基金管理有限公司：王俊杰 | | | | 农银汇理基金管理有限公司：徐治彪 | | | 广发证券股份有限公司:吴文华 | | | | | 广州瑞民投资管理有限公司：黄晓坤 | | 时间 | 2016-06-08 | | | 地点 | 公司会议室 | | | ...

广州市香雪制药股份有限公司 2022 年第三季度报告 证券代码：300147 证券简称：香雪制药 公告编号：2022—082 广州市香雪制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、 误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息 的真实、准确、完整。 3.第三季度报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末 | | --- | --- | --- | --- | --- | | | | 增减 | | 比上年同期增减 | | 营业收入（元） | 554,612,486.43 | -20.88% | 1,745,600,746.67 | -21.95 ...

Financial Performance - The net profit attributable to shareholders for 2021 was -688.4691 million RMB, primarily impacted by the pandemic, medical policies, market competition, impairment provisions, and financial expenses [5]. - The company's operating revenue for 2021 was CNY 2,970,575,841.91, a decrease of 3.30% compared to CNY 3,072,090,655.97 in 2020 [23]. - The net profit attributable to shareholders was a loss of CNY 688,469,145.4, representing a decline of 799.51% from a profit of CNY 98,420,950.34 in 2020 [23]. - The basic earnings per share for 2021 was -CNY 1.04, down 793.33% from CNY 0.15 in 2020 [23]. - The total assets at the end of 2021 amounted to CNY 11,380,592,438, a decrease of 6.69% from CNY 12,196,636,876 at the end of 2020 [23]. - The net assets attributable to shareholders decreased by 18.47% to CNY 2,945,552,554.18 from CNY 3,612,685,390 at the end of 2020 [23]. - The total profit for 2021 was CNY -635.78 million, a decrease of 482.68% year-on-year [61]. - The company reported a total revenue of CNY 297,057.58 million in 2021, a decrease of 3.30% year-on-year, with a net profit attributable to shareholders of CNY -68,846.91 million, down 799.51% [72]. Strategic Plans and Governance - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves [8]. - Future plans and forward-looking statements are subject to risks, and investors are advised to understand the differences between plans, forecasts, and commitments [7]. - The company will continue to improve governance and assessment across various business segments [5]. - The company emphasizes its core competitiveness and sustainable operational capabilities, aiming to enhance profitability and achieve steady growth [5]. - The company is committed to optimizing asset structure and resource allocation to enhance core competitiveness and promote sustained growth in performance [51]. - The company aims to enhance market share through brand advantages and product promotion, while focusing on industry advantages to drive technological innovation [51]. - The company is focused on maintaining the interests of all shareholders, especially minority shareholders, through fair pricing in related transactions [186]. Industry Challenges and Opportunities - The pharmaceutical industry is facing challenges and opportunities due to the dual impact of the pandemic and medical policies, with significant government policies aimed at reducing drug prices [5]. - The transition of the pharmaceutical industry from rapid growth to high-quality development presents both challenges and opportunities [5]. - The company has faced significant pressure from policies such as "volume-based procurement" and "two-invoice system," which have led to increased competition and reduced drug prices [48]. - The company has been impacted by the government's policies aimed at reducing drug prices and improving the efficiency of the pharmaceutical supply chain [48]. Research and Development - The company has developed a complete TCR-T technology platform for tumor-specific antigen discovery and TCR screening, achieving international advanced levels [64]. - The company is actively exploring various R&D models, including independent research, technology transfer, and collaborative development [60]. - The company is currently conducting Phase I clinical trials for a new small molecule drug aimed at treating malignant gliomas [94]. - The company is accelerating clinical trials for the new drug TAEST16001 injection and expanding its research pipeline in cell immunotherapy [125]. Market Dynamics - The pharmaceutical industry in China saw a drug sales growth of 8.8% year-on-year in the first half of 2021, with total sales reaching 839.3 billion yuan [35]. - Public medical institutions accounted for the largest share of drug sales at 63.8%, followed by retail pharmacies at 26.4% and public grassroots medical institutions at 9.8% [35]. - The revenue of listed pharmaceutical companies in the first three quarters of 2021 reached 1,583 billion yuan, a year-on-year increase of 18.88%, with net profit attributable to shareholders growing by 25.3% [36]. - The traditional Chinese medicine (TCM) sector experienced revenue and net profit growth rates of 11.28% and 20.77% respectively in the first three quarters of 2021 [36]. Operational Efficiency - The company has established a comprehensive supply chain management system to maximize production capacity utilization and ensure product supply quality [70]. - The company has implemented a strategic procurement model to ensure stable and high-quality material supply, with a focus on long-term partnerships [56]. - The company has established a GMP-compliant quality management system to ensure product quality from R&D to commercialization [69]. - The company has a commitment to technological innovation, with a dedicated research and development center led by Kang Zhiying [176]. Employee and Management Structure - The total number of employees at the end of the reporting period was 3,378, with 1,082 in the parent company and 1,905 in major subsidiaries [187]. - The company has a professional composition of 1,192 production personnel, 680 sales personnel, 706 technical personnel, 98 financial personnel, 303 administrative personnel, and 399 others [187]. - The company has implemented a salary policy that includes basic salary, performance salary, bonuses, social security, housing fund, and living allowances, linking sales personnel's salaries to individual sales performance [188]. - The company has established a scientific assessment system to enhance employee motivation and align compensation with company performance [188]. Corporate Governance - The company emphasizes the importance of information disclosure, adhering to regulations and ensuring timely and accurate communication with investors [153]. - The company maintains independence from its controlling shareholders in business, personnel, assets, organization, and finance, ensuring a complete operational system [155]. - The company has a robust governance structure that complies with legal and regulatory requirements, with no significant discrepancies noted [154]. - The company has a diverse board of directors and management team, with ongoing changes in shareholding among key personnel [159]. Financial Management - The company has established a risk internal control management organization to supervise and evaluate internal control management [200]. - The internal control design is sound and reasonable, with no significant omissions identified in the evaluation [200]. - The company has a complete and independent financial accounting system, ensuring autonomous financial decision-making [157]. - The company reported a fair value change of CNY 9,366,578.75 for its financial assets, with a total initial investment cost of CNY 124,720,151.66 [114].

Financial Performance - The company's revenue for Q3 2021 was ¥700,940,780, representing a 3.38% increase compared to ¥678,000,020 in the same period last year[4]. - The net profit attributable to shareholders was a loss of ¥33,412,770, a decrease of 595.06% from a profit of ¥6,749,185 in the previous year[4]. - Total operating revenue for Q3 2021 was CNY 2,236,452,584.17, a decrease of 10.35% compared to CNY 2,494,461,040.41 in the same period last year[20]. - Net profit for Q3 2021 was CNY 47,734,307.87, a significant decline of 73.5% from CNY 180,045,818.85 in Q3 2020[22]. - The net profit attributable to shareholders of the parent company was CNY 16,894,395.35, down 88.6% from CNY 147,886,620.46 in the previous year[22]. - The company reported a total comprehensive income of CNY 48,668,039.84, compared to CNY 178,656,822.52 in Q3 2020, a decrease of 72.8%[22]. Cash Flow - The net cash flow from operating activities increased by 1460.23%, reaching ¥168,367,470 compared to a loss of ¥12,377,840 in the previous year[4]. - The net cash flow from operating activities was 168,367,470.08 CNY, a significant improvement compared to a loss of 12,377,848.16 CNY in the previous period[25]. - Total cash inflow from operating activities was 2,383,865,867.55 CNY, down 10.55% from 2,665,729,201.18 CNY in the prior period[25]. - Cash outflow from operating activities totaled 2,215,498,397.47 CNY, a decrease of 17.29% from 2,678,107,049.34 CNY in the previous period[25]. - The net cash flow from investing activities was -304,319,283.56 CNY, an improvement from -829,642,669.40 CNY in the prior period[26]. - Cash inflow from financing activities was 3,577,598,708.10 CNY, an increase from 3,075,980,000.00 CNY in the previous period[26]. - The net cash flow from financing activities was -196,824,471.30 CNY, compared to a positive flow of 1,370,285,846.44 CNY in the prior period[26]. - The ending balance of cash and cash equivalents was 144,566,701.01 CNY, down from 862,078,289.23 CNY in the previous period[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥11,636,374,813.18, a decrease of 4.59% from ¥12,196,636,876.12 at the end of the previous year[5]. - Total liabilities decreased to CNY 7,176,204,513.48 from CNY 7,947,453,059.37, a decline of 9.7%[18]. - The total equity of the company reached approximately CNY 4.25 billion, with total assets amounting to CNY 12.20 billion[31]. - The company holds CNY 725.72 million in long-term loans and CNY 221.20 million in bonds payable[30]. - The report indicates a total of CNY 85.01 million in contract liabilities, reflecting future revenue obligations[30]. Investments and R&D - The company reported a significant increase in R&D expenses by 44.18%, indicating higher investment in ongoing projects[10]. - The company's R&D expenses increased to CNY 49,336,607.34, up from CNY 34,219,547.32, representing a growth of 44.3%[21]. - The company made a strategic investment in SIRNAOMICS LTD, resulting in a 114.18% increase in other non-current financial assets[10]. - The company experienced a 67.25% increase in other income related to government subsidies, reflecting enhanced support from governmental policies[10]. - The company reported a 16247.33% increase in cash received from investments, indicating a significant inflow from new investments[10]. Shareholder Information - The company’s major shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 26.22% of the shares, with a total of 173,390,578 shares pledged[13]. - The total owner's equity attributable to shareholders is approximately CNY 3.61 billion[31]. Miscellaneous - The company has not undergone an audit for the third quarter report[32]. - The report was released by the board of directors on October 27, 2021[33].

Financial Performance - The company's revenue for Q1 2021 was ¥790,928,290.30, a decrease of 0.87% compared to ¥797,838,222.65 in the same period last year[7] - Net profit attributable to shareholders was ¥24,623,120.43, down 69.51% from ¥80,770,022.98 year-on-year[7] - The net profit after deducting non-recurring gains and losses was ¥27,052,442.76, a decline of 70.32% compared to ¥91,147,638.79 in the previous year[7] - Basic and diluted earnings per share were both ¥0.040, down 66.67% from ¥0.120 in the previous year[7] - The weighted average return on equity was 0.68%, a decrease of 1.60% from 2.28% in the same period last year[7] - The company's operating revenue for the reporting period was 790.93 million yuan, a decrease of 87% compared to the same period last year[16] - Net profit attributable to shareholders was 24.62 million yuan, down 69.64% year-on-year[16] - The company reported a total comprehensive income of CNY 32,228,268.28, compared to CNY 82,135,469.34 in the previous year[50] - The net profit for the first quarter of 2021 was CNY 22,123,960.73, a decrease from CNY 82,703,544.91 in the same period last year, representing a decline of approximately 73.24%[53] - Operating profit for the first quarter was CNY 25,823,873.58, down from CNY 85,895,272.29 year-over-year, indicating a decrease of about 69.91%[53] Cash Flow and Assets - The net cash flow from operating activities was ¥47,990,276.62, a significant improvement from a negative cash flow of ¥434,108,600.96 in the same period last year[7] - The company's cash flow from other operating activities increased by 46.14% due to an increase in cash received from other business units[15] - Cash inflow from operating activities totaled CNY 957,745,229.37, compared to CNY 853,594,016.22 in the previous year, reflecting an increase of approximately 12.21%[56] - The ending balance of cash and cash equivalents was CNY 259,954,128.17, a decrease from CNY 1,020,941,657.52 at the end of the previous year[58] - The company's cash and cash equivalents decreased to CNY 475,853,970.63 from CNY 605,136,289.00, representing a decline of approximately 21.4%[39] - The total cash flow from financing activities resulted in a net outflow of CNY -123,256,693.16, contrasting with a net inflow of CNY 1,270,994,957.53 in the previous year[58] Investments and Research - The company is conducting Phase I clinical trials for a new drug KX02 for the treatment of glioblastoma, which is a significant part of its new drug development and technological innovation[17] - The company is also developing a new TCR-T cell therapy drug, TAEST16001, which aims to enhance its position in the field of immunotherapy for solid tumors[17] - The company has completed basic research on a new peptide drug for respiratory virus infections and is currently conducting preclinical studies[17] - The company plans to invest significantly in the TAEST16001 clinical trial and other research pipelines over the next 1 to 2 years[28] - Research and development expenses rose to CNY 12,291,047.83 from CNY 9,803,456.18, indicating a focus on innovation[48] Shareholder and Equity Information - Net assets attributable to shareholders were ¥3,641,158,860.32, up 0.68% from ¥3,616,535,739.89 at the end of the previous year[7] - The total number of ordinary shareholders at the end of the reporting period was 51,469[11] - The controlling shareholder, Guangzhou Kunlun Investment Co., Ltd., transferred 66,000,000 shares of the company, representing 9.9794% of the total share capital, at a price of 5.98 RMB per share, totaling 394,680,000 RMB[29] - The company repurchased and canceled 114,900 restricted shares from seven former incentive plan participants, accounting for 0.0174% of the total share capital, at a repurchase price of 3.274 RMB per share, totaling 376,182.6 RMB[31] - The total share capital of the company decreased from 661,476,335 shares to 661,361,435 shares after the cancellation of the repurchased shares[31] Operational Challenges and Strategies - The company is closely monitoring the impact of macroeconomic uncertainties and ongoing medical reforms on its operations and is preparing to adapt its strategies accordingly[19] - The company is focusing on reducing risks associated with accounts receivable by implementing strict credit management policies[23] - The company is expanding its business operations across multiple provinces in China, including Hong Kong, Guangdong, and Sichuan, which increases management complexity[23] - The company is actively addressing a lawsuit involving an investment dispute, with a claim amount of 40 million yuan[23] Collaborations and Regulatory Matters - The company is collaborating with ATHENEX, INC. on the oral paclitaxel product, which has not yet received FDA approval for its new drug application[21] - The company has obtained the first IND for TCR-T cell therapy in China, with the TAEST16001 currently in Phase I clinical trials[21] - The FDA has issued a complete response letter regarding the oral paclitaxel application, indicating that the application has not been approved in its current form[27] - The company aims to optimize its new drug application strategy for oral paclitaxel in accordance with FDA feedback and will proceed with registration in China[27] Financial Position and Liabilities - Total assets at the end of the reporting period were ¥9,878,792,818.46, an increase of 1.03% from ¥9,778,169,416.01 at the end of the previous year[7] - Total liabilities were CNY 5,593,530,383.63, up from CNY 5,525,135,249.46, indicating an increase of about 1.23%[41] - Short-term borrowings decreased significantly to CNY 2,421,007,389.68 from CNY 2,881,303,514.38, a reduction of approximately 15.9%[40] - Total operating costs increased to CNY 752,046,996.21 from CNY 702,098,650.73, with operating costs specifically rising from CNY 494,782,388.47 to CNY 554,772,200.94[48]

Financial Performance - Operating revenue for the period reached ¥678,000,027.80, up 2.98% year-on-year, while year-to-date revenue increased by 25.78% to ¥2,494,461,040.41[7] - Net profit attributable to shareholders decreased by 81.40% to ¥6,749,185.79 for the quarter, but increased by 60.41% to ¥147,886,620.46 year-to-date[7] - Basic earnings per share for the quarter were ¥0.01, down 80.00%, while year-to-date earnings per share were ¥0.22, up 57.14%[7] - Operating profit increased by 68.67% driven by synchronized growth in sales and profitability of key products[19] - Total profit rose by 47.61% as a result of increased sales and profitability of main products[19] - Net profit increased by 30.54% due to synchronized growth in sales and profitability of major products[20] - Net profit attributable to shareholders increased by 60.41% driven by sales growth[20] - Basic and diluted earnings per share rose by 59.69% as a result of increased sales[20] Cash Flow and Liquidity - The net cash flow from operating activities was ¥128,370,166.24, a significant increase of 208.71% compared to the same period last year[7] - Cash and cash equivalents increased by 113.26% due to increased operating income and borrowings[19] - Cash received from tax refunds increased by 92.36% due to higher government subsidies[20] - Cash flow from operating activities decreased by 125.88% primarily due to increased inventory reserves[20] - The company reported a total cash outflow from investing activities of 1,016,346,751.04 CNY, compared to 777,465,495.33 CNY in the previous year, representing an increase of approximately 30.7%[62] - The ending balance of cash and cash equivalents was 862,078,289.23 CNY, up from 374,695,542.59 CNY, reflecting a significant increase of about 130.0%[62] Assets and Liabilities - Total assets increased to ¥9,938,317,051.69, representing a 23.33% increase compared to the previous year[7] - The company's current assets reached CNY 3,819,714,880.39, up from CNY 2,696,899,709.18 in the previous year, indicating a year-over-year increase of about 41.6%[33] - Total liabilities increased to CNY 5,671,699,573.29 from CNY 3,943,011,596.49, reflecting a growth of about 43.9% year-over-year[36] - Current liabilities rose to CNY 4,507,029,489.17, up from CNY 2,856,107,381.53, indicating an increase of approximately 57.7%[36] - Long-term borrowings increased by 36.54% as part of optimizing the financing structure for project loans[19] Shareholder Information - The total number of shareholders at the end of the period was 46,299, with the top ten shareholders holding a combined 40.44% of the shares[11] - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., held 33.67% of the shares, amounting to 222,708,046 shares[11] Research and Development - Development expenses surged by 177.58%, primarily due to accelerated investment in research projects[19] - Research and development expenses were CNY 12.9 million, down from CNY 17.8 million, showing a reduction of about 27%[43] - Research and development expenses for Q3 2020 were CNY 34,219,547.32, slightly down from CNY 36,952,245.85 in the same quarter last year[56] Legal and Compliance - The company is involved in legal disputes regarding capital increase and contract issues with various entities[21] - The company reported no violations regarding external guarantees during the reporting period[28] - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[28] Market and Investment Activities - The company has made investments in new subsidiaries related to ginseng market management[22] - The company plans to continue collaboration with ATHENEX, INC. on the commercialization of new products[21] Other Financial Metrics - The weighted average return on equity was 0.19% for the quarter, a decrease of 0.84% year-on-year, while it was 4.15% year-to-date, an increase of 1.50%[7] - Financial expenses decreased by 31.67% due to lower financing rates and increased interest subsidies[19] - The company reported a significant increase of 24219.65% in fair value changes due to market price fluctuations of Athenex, Inc. stock[19]

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 1,816,461,012.61, representing a 37.11% increase compared to CNY 1,324,792,550.99 in the same period last year[19]. - The net profit attributable to shareholders of the listed company reached CNY 141,137,434.67, a significant increase of 152.47% from CNY 55,902,758.23 in the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 137,998,199.28, which is a remarkable increase of 1,645.48% compared to CNY 7,906,045.43 in the same period last year[19]. - The basic earnings per share increased to CNY 0.21, up 162.50% from CNY 0.08 in the previous year[19]. - The total assets of the company at the end of the reporting period were CNY 9,813,566,076.60, reflecting a 21.78% increase from CNY 8,058,122,766.05 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were CNY 3,611,198,698.76, which is a 3.42% increase from CNY 3,491,873,357.43 at the end of the previous year[19]. - The company reported a net cash flow from operating activities of CNY -140,748,014.40, a decrease of 2,357.13% compared to CNY 6,235,720.26 in the previous year[19]. - The weighted average return on net assets was 3.96%, an increase of 2.34% from 1.62% in the previous year[19]. Business Operations - The main business focuses on the research, production, and sales of modern traditional Chinese medicine and related products, with a product system including antiviral oral liquids and granules[26]. - The company has established a full industry chain layout from traditional Chinese medicine planting to production and distribution, enhancing its market position[26]. - The sales model is shifting from a distributor model to direct management of end customers, increasing control over sales terminals[32]. - The COVID-19 pandemic significantly boosted demand for the company's products, leading to rapid growth in overall business performance[33]. - The company is actively developing precision medical treatments targeting tumors, integrating gene diagnosis and immunotherapy[26]. - The procurement of raw materials is managed through a centralized supply chain system, ensuring stable and high-quality material supply[28]. - The company adheres to national GMP standards in production, ensuring compliance with quality regulations[31]. Market and Industry Trends - The pharmaceutical industry is experiencing strong growth due to increasing healthcare demands driven by aging populations and rising health awareness[34]. - The government is promoting the development of traditional Chinese medicine, which is expected to enhance the industry's growth prospects[35]. Product Development and Innovation - The company is conducting clinical trials for several new drugs, including KX02 for glioblastoma and STP705 for scar-free wound healing, enhancing its product portfolio[55]. - The company developed new epidemic prevention products, including "Yue Anti No. 1" herbal tea and "Yue Anti No. 1" special herbal tea granules, in response to public health needs[49]. - The company has established a mask production line and a sterile workshop to meet the demand for protective equipment during the pandemic[49]. Financial Strategy and Investments - The company plans to raise up to 1.4 billion yuan through a private placement of shares to support key project construction and supplement working capital[54]. - The company made a significant equity investment of CNY 4,000,000 in Xiangxue Medical Technology (Beijing) Co., Ltd., holding an 80% stake[71]. - The company has ongoing non-equity investments totaling CNY 217,654,000 across various medical-related projects, with a cumulative actual investment of CNY 1,683,080,000[74]. Risk Management - The company has outlined potential risks and corresponding measures in its report, which investors are advised to pay attention to[5]. - The company faces risks from policy changes in the healthcare sector, which could impact its operations and market dynamics[86]. - The company has established a strategic layout to secure the supply of traditional Chinese medicinal materials, aiming to mitigate the impact of price fluctuations in this sector[88]. Corporate Governance and Compliance - The company received a warning letter from the China Securities Regulatory Commission and a public criticism from the Shenzhen Stock Exchange, and has taken corrective measures accordingly[144]. - The auditor issued a qualified opinion due to the inability to obtain sufficient audit evidence regarding the completeness of related party transactions[105]. - The board of directors acknowledged the auditor's qualified opinion and stated that it would not have a significant impact on the company's financial position and operating results for 2019[107]. Community Engagement and Social Responsibility - The company donated a total of 1,450 boxes of antiviral oral liquid and 6,726 boxes of "Yue Anti No. 1" herbal tea to various groups, including healthcare workers and community prevention personnel[52]. - The company has actively engaged in community support and public health initiatives, including free online consultations and medical services[52]. Shareholder Information - The total number of shares outstanding is 661,476,335, with 98.48% being unrestricted shares[155]. - The largest shareholder, Guangzhou Kunlun Investment Co., Ltd., holds 34.24% of the shares, totaling 226,488,046 shares[157]. - The company does not have any preferred shares or convertible bonds during the reporting period[163][166]. Environmental Compliance - The company has established a wastewater treatment facility with a design capacity of 360 m³/d, ensuring compliance with national discharge standards[137]. - The company has invested in professional equipment to ensure that wastewater and exhaust emissions meet national standards[137]. - The company has reported no significant environmental pollution incidents during the reporting period[136].